New Arctic search and rescue watch adds durable features
A company that's been constructing military-grade watches for the U.S., Canada and other nations since World War II has added an arctic version of a premier search and rescue watch to its inventory.
Company owner Mitchell Wein's grandfather had the good fortune of housing his watchmaking business in the same building as the Canadian Army's procurement office as the nation entered the WWII.
It had only been a few years since the Marathon Watch founder had broken off from the family watch business to design his own product.
Those first watches went on the wrists of soldiers headed to fight in Italy. The company eventually delivered an estimated 160,000 watches during WWII, Wein said, and has remained in the military watch game nearly ever since.
'Combining military-grade durability with precise engineering, the Original Search and Rescue with Date, or OSAR-D, builds on Marathon Watch's legacy of the original 41mm SAR, which set the standard for Search and Rescue timepieces in the early 2000s,' according to a company release.
The expanded OSAR-D family of watches maintains the enhanced features introduced last year with the launch of the 41mm OSAR-D with black dial.
Those include the improved MaraGlo illumination, larger indices and increased clarity on the cyclops date window.
The company also added the Arctic white dial, which is designed to improve legibility in bright conditions, offering unparalleled readability in extreme environments.
All the company's timepieces are powered by Marathon x Sellita automatic movements. The SW-200 movement drives 36mm and 41mm sizes.
The 46mm jumbo edition is equipped with the new SW600 movement, which includes a 62-hour power reserve, now the largest power reserve Marathon has to date.
Each OSAR-D model is also fitted with an Incabloc shock absorber to reinforce its durability.
The 41mm size watches are available for preorder, with shipments slated for mid-May, company officials said. Prices start at $1,500 with the 3-piece rubber strap kit. The stainless steel bracelet option costs $1,800.
The 36mm and 46mm sizes will be available in late 2025, with prices ranging from $1,000 to $2,500.
The company built its general-purpose mechanical watch in 1976 for the U.S. military and started building chronometers for ships in the early 1980s, Wein said.
'We didn't really make money on the government watches,' Wein said, adding that they would get orders of 7,000 or 11,000 watches and make between $3.50 and $5 per watch.
One of the reasons mechanical watches remain part of military inventory in an age of their smart counterparts is that mechanical timekeeping remains impervious to electromagnetic pulse tactics that could blow out any electronics in range. They also do not emit a signal that can be detected by electromagnetic warfare tools.
And then there's the battery, or lack thereof, which adds to their long-lasting durability. The watch can operate for 30 years, as compared to a traditional quartz watch that usually requires a new battery every six years.
Special, synthetic oil blends keep the watch going. Those only need replacement every 15 years or so, Wein said. Tritium gas tubes that provide glow in the dark features stay bright for 12 to 25 years.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Medicus Pharma Ltd. to Present at 2025 Bio International Convention
Company Executive Chairman & CEO to Provide Corporate Updates on June 17th 2025 Philadelphia, Pennsylvania--(Newsfile Corp. - June 12, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the schedule of the presentation of Dr. Raza Bokhari, Executive Chairman and CEO, at 2025 Bio International Convention. Event DetailsDate: Tuesday, June 17, 2025Time: 3:15 p.m. ETLocation: Room 153A, Boston Convention & Exhibition Center The Company's lead asset, SkinJect Inc., is a development stage biotechnology company focused on commercializing a novel treatment for non-melanoma skin cancer, especially basal cell carcinoma (BCC), using a patented dissolvable doxorubicin-containing microneedle array (D-MNA). D-MNA delivers the chemotherapeutic agent transdermally at the site of the lesion to eradicate tumor cells. The Company is currently conducting a Phase 2 clinical study SKNJCT-003 in nine (9) clinical sites across United States which commenced randomizing patients in August 2024. In March 2025 the Company also announced a positively trending interim analysis for SKNJCT-003 demonstrating more the 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board increased the number of participants in SKNJCT-003 to Ninety (90) subjects. The Company also announced expanding clinical trial sites in Europe. The Company also has a clinical design (SKNJCT-004) currently underway in United Arab Emirates (UAE). The study is expected to randomize 36 patients in four sites in UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company. In April 2025, the Company announced entering into a binding letter of intent to acquire Antev Ltd. ("Antev"), a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate. For further information contact: Carolyn Bonner, President (610) 636-0184cbonner@ Anna Baran-Djokovic, SVP Investor Relations (305) 615-9162adjokovic@ About Medicus Pharma Ltd: Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd, is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumors cells. The Company has completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in UAE. In April 2025, the Company also announced entering into a binding letter of intent to acquire Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate. The transaction with Antev is subject to the completion of satisfactory due diligence by Medicus, negotiation of definitive agreements, obtaining applicable corporate, regulatory and other third-party approvals and the fulfillment of customary closing conditions. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transactions will be consummated on the terms or timeframe currently contemplated, or at all. Cautionary Notice on Forward-Looking Statements Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the commencement of the SKNJCT-004 study and the potential results of and benefits of such study, the potential Antev transaction, including the entry into a definitive agreement in respect of the Antev transaction, the closing of the transaction or the timing thereof, the potential benefits of the Antev transaction, if consummated, including plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix, and the potential market opportunities related thereto, the results of the interim analysis, which may or may not correlate with the findings of the clinical study report that will be compiled following completion of the phase 2 study, the Company's plans and expectations concerning, and future outcomes relating to, the submission and advancement of the phase 2 clinical protocol, the randomization of patients and size of the study, the Company's intention to complete and submit an interim data analysis to the FDA and to request a Type C meeting and the timing thereof, the Company's aim to fast fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof. Forward-looking statements are often but not always, identified by the use of such terms as "may", "on track", "aim", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target" or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company's public filings on EDGAR and on SEDAR+, which may impact, among other things, the trading price and liquidity of the Company's common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are cautioned that the foregoing list is not exhaustive, and readers are encouraged to review the Company's long form prospectus accessible on the Company's profile on EDGAR at and on SEDAR+ at Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Newsweek
2 hours ago
- Newsweek
Ducati Expands Off the Road to Gain New Buyers
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. For 80 years, Ducati has been known as an Italian motorcycle company, part of a post-World War II product evolution toward affordable, practical transportation. In the years since, the brand has evolved to be a performance champion. For decades, companies including Yamaha, Kawasaki, Suzuki, Honda, KTM and Husqvarna have dominated the dirt bike industry. In 2025, Ducati will evolve its lineup further, entering the dirt bike segment for the first time to compete against them. Ducati North America CEO Jason Chinnock told Newsweek that the move comes at a pivotal time for the company and off-road motorcycling. "There has been a significant increase in off-road racing both on the professional and amateur levels. Competition is central to Ducati's DNA, and with the new off-road models we will launch over the coming years, supported by both a professional and grassroots racing program, is perfectly aligned," he said. The move into dirt bikes has been a long time coming. For many Ducati employees, the passion for off-roading started when they were kids. Chinnock reminisced: "For many of us at Ducati, our passion for motorcycling began with riding dirt bikes as it was also the first motorcycling experience for most Americans (as it was for myself). Expanding into off-road is a natural evolution for a brand deeply rooted in two-wheel performance and racing." A rider jumps with a Ducati Desmo450 MX. A rider jumps with a Ducati Desmo450 MX. Ducati Racing is core to dirt bike brand visibility and marketing efforts, and it is growing in popularity in one of Ducati's key markets, North America. "Off-road motorcycling is experiencing significant global growth, especially in North America. As an example, the new NBC/Peacock live broadcasts of SuperMotocross race events have increased the sport's visibility and reach. With 1.1 million total annual attendees, SuperMotocross connects with a wide and youthful audience. This makes it the ideal time for Ducati to enter the space and engage a new generation of riders as we continue to grow our brand," he said. Ducati plans to enter the market as a premium dirt bike competitor, positioning that aligns with its other motorcycle offerings. "As the aspirational motorcycling brand, Ducati is uniquely positioned to fulfill that demand with a premium motorcycle with a distinct character, exciting performance and built to our exacting standards—offering top-tier technology off the showroom floor at a competitive price making it accessible to the audience," Chinnock said. The first dirt bike Ducati will bring to market is the Desmo450 MX. It starts at $11,495 and is intended for use only in closed-course circuits. Production of the model began in late May at the company's Borgo Panigale factory in Bologna, Italy. The Ducati Desmo450 MX is driven through mud on a closed course. The Ducati Desmo450 MX is driven through mud on a closed course. Ducati "With the Desmo450 starting from a clean sheet, we were able to innovate key components like the chassis, engine, and electronics, leveraging our legacy of performance, innovation, and exclusive technologies," Chinnock explained. The company utilized its paved track motorcycle learnings to influence the development of the Desmo450. "Our experience winning the last three consecutive years in MotoGP has led to the development of groundbreaking technologies, such as the first off-road closed-loop traction control system, ultimately strengthening rider confidence while riding," he said. "The Desmo450 motor is also exclusive to off-road motorcycling, which features our signature Desmodromic Valve System. This offers the rider the ability to maximize every gear at the start and through corners, thanks to its particularly favorable power delivery, which combines torque at low and medium revs with impressive over-revving abilities. The frame is a unique aluminum structure characterized by the least possible number of welds, thus hitting the desired targets of lightness, reliability, and rigidity. The result of these innovations is a motorcycle that delivers exceptional performance while remaining highly rideable for a diverse range of riders," Chinnock said. Ducati intends to imbue each of its off-roading motorcycles with the same level of craftsmanship, precision engineering and attention to detail that the rest of its lineup receives. The Desmo450's "outstanding ergonomics and class-leading power create a motorcycle that is not only incredibly powerful but also intuitive, rideable, and enjoyable on any terrain," the CEO said. A rider drives the Ducati Desmo450 MX around a closed course. A rider drives the Ducati Desmo450 MX around a closed course. Ducati Ducati has appointed 55 percent of its U.S. dealer network (130 total dealers) as authorized off-road dealers for the Desmo450. Its Multistrada family was the best-selling motorcycle of 2024 for Ducati, exceeding 13,000 motorcycles delivered. Ducati delivered 54,495 motorcycles worldwide in 2024, with the U.S. accounting for 6,993 of those.
Yahoo
3 hours ago
- Yahoo
Poundland sold for less than £1
Poundland has been sold to the former owner of Laura Ashley for less than £1. Gordon Brothers, which backs distressed companies, has agreed to provide £80m of fresh funding as part of a rescue deal for the struggling discount retailer. The €1 (85p) sale was thrashed out overnight after the Telegraph revealed that Poundland had failed to keep up with business rates payments to scores of local councils up and down the country. With the company being chased for millions of pounds in unpaid bills, advisers scrambled to prevent the talks with Gordon Brothers from collapsing. Poundland's Polish parent Pepco has been scrambling to offload the business after it became a serious drag on profitability. Pepco crashed to a £548m paper loss in December after slashing the value of its UK arm by nearly £650m, with bosses blaming a 'significant decline in performance' and spiralling costs. Yet the sale to Gordon Brothers, which used to own Laura Ashley, represents only a partial reprieve for one of the largest retailers in the country. As part of a sweeping restructuring plan drawn up by Poundland's existing senior management, the business plans to take the axe to its sprawling estate of more than 800 stores as it desperately seeks to rein in costs. Around 150 shops have been earmarked for immediate closure, but it is thought as many as 200 could ultimately be jettisoned at the cost of thousands of jobs. The move would also represent another painful blow to Britain's dwindling high streets. The company has also identified a further 500 stores where it hopes to impose steep rent cuts on landlords. Reductions of anywhere between 10pc and 50pc will be asked for. Despite being several months in arrears on business rates, Poundland is also weighing a request for a freeze on further payments. The radical measures will be put to a High Court judge in the coming weeks for approval. Gordon Brothers said it would provide up to £80m 'to support the management team's proposed restructuring and turnaround plan'. Pepco has also agreed to provide a £30m loan as well as roll over £30m of existing debt. The sale 'marks an important milestone in our strategic plan to move away from FMCG and focus predominantly on Pepco, our higher margin clothing and general merchandise business', Stephan Borchert, Pepco's chief executive, said. 'Poundland remains a key player in UK discount retail, with millions of customers annually and a well-loved brand and proposition,' he added. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data